ARTICLE | Finance
Good start for Incivek
Vertex HCV drug Incivek beats initial Street expectations, Merck's Victrelis
August 1, 2011 7:00 AM UTC
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) ticked down all last week in the run-up to its earnings day. But the stock regained all the lost ground and more after the first sales numbers for HCV drug Incivek telaprevir showed that it beat both Merck & Co. Inc.'s Victrelis boceprevir and analyst expectations.
After sinking $3 to $47.98 in the four days prior toThursday's postmarket earnings announcement, Vertex jumped $3.88 on Friday to close the week up $0.88 at $51.86...